Markets

Monsanto (MON) Beats on Q3 Fiscal 2017 Earnings & Revenues

Monsanto CompanyMON has carved a name for itself in the global agricultural chemicals' industry. The company tries to enhance the yield and quality of several commercial and non-commercial agricultural crops such as cotton, soybean and corn.

Currently, MON has a Zacks Rank #2 (Buy), but that could definitely change after the release of its third-quarter fiscal 2017 (ended May 31, 2017) results. You can see the complete list of today's Zacks #1 Rank stocks here .

We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: MON reported adjusted earnings of $1.93 per share in third-quarter fiscal 2017 (on an ongoing basis), above the Zacks Consensus Estimate of $1.74 per share.

Revenue: MON posted revenues of $4,230 million in third-quarter fiscal 2017, higher than the Zacks Consensus Estimate of $4,089 million.

Key Factors: MON confirms to report adjusted earnings at the high-end of the $4.50-$4.90 per share range for fiscal 2017, on an ongoing basis.

MON aims to underpin its business on the back of improved core seeds and genomics business, strategic management of agricultural productivity segment's trade, meaningful restructuring and appropriate investments.

The company perceives to successfully close Bayer AG's BAYRY buyout deal by the end of calendar year 2017.

Stock Price: At the time of writing, the stock price of MON was up nearly 0.64% ($0.75) in the pre-market trade on Nasdaq. Clearly the initial reaction to the release is positive. We view the company's better-than-expected third-quarter fiscal 2017 results as the primary reason responsible for this positive sentiment.

As of Jun 27, 2017, MON's stock closed the trading session at $117.25 per share.

Monsanto Company Price

Monsanto Company Price | Monsanto Company Quote

Check back our full write up on this MON earnings report later!

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bayer AG (BAYRY): Free Stock Analysis Report

Monsanto Company (MON): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BAYRY

Other Topics

Earnings Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More